CRISPR Therapeutics to present Phase 1b CTX310 data at AHA 2026
CRISPR Therapeutics said it will present late-breaking clinical data from its Phase 1b trial of CTX310, its in vivo CRISPR/Cas9 gene editing therapy targeting ANGPTL3, at the American Heart Association (AHA) Scientific Sessions 2026.